Clinical efficacy of istradefylline in dyskinetic patients with Parkinson’ disease

Abstract

Background: Istradefylline is a selective adenosine A2A receptor antagonist and has efficacy in reducing OFF time in Parkinson’ Disease (PD) patients with motor complications on levodopa therapy. However, the efficacy is mild. The adenosine A2A receptors in putamen are increased in the PD patients with dyskinesia. This finding suggests that clinical efficacy of Istradefylline may be different between dyskinetic patients and nondyskinetic patients with PD.